New Breast Cancer Resistance Mechanism Against Drug Treatment Revealed

New Breast Cancer Resistance Mechanism Against Drug Treatment Revealed
shutterstock_137334872 IIA study published in the journal Cell Cycle revealed a new mechanism by which breast cancer cells resist to drug treatment. The study is entitled “Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells” and was conducted at Dartmouth’s Geisel School of Medicine and Norris Cotton Cancer Center in Lebanon and Hanover, New Hampshire. The receptor tyrosine kinase ERBB2 gene is known to play an important role in the development of aggressive types of breast cancer, and is associated with increased recurrence. Therapies have been developed against ERBB2 but usually patients develop resistance to the treatment. “Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival,” said the senior author of the study Dr. Manabu Kurokawa in a news release. “Current therapies take advantage of this by using targeted drugs such as Trastuzumab or Lapatinib to specifically inhibit ERBB2, but eventual
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.